Supernus Pharmaceuticals (SUPN) Competitors $48.31 -0.04 (-0.08%) Closing price 04:00 PM EasternExtended Trading$49.20 +0.89 (+1.84%) As of 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SUPN vs. CORT, JAZZ, PRGO, PCRX, NKTR, OMER, ASMB, CPIX, LLY, and JNJShould you be buying Supernus Pharmaceuticals stock or one of its competitors? The main competitors of Supernus Pharmaceuticals include Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), and Johnson & Johnson (JNJ). These companies are all part of the "pharmaceuticals" industry. Supernus Pharmaceuticals vs. Its Competitors Corcept Therapeutics Jazz Pharmaceuticals Perrigo Pacira BioSciences Nektar Therapeutics Omeros Assembly Biosciences Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson Corcept Therapeutics (NASDAQ:CORT) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk. Is CORT or SUPN more profitable? Corcept Therapeutics has a net margin of 18.51% compared to Supernus Pharmaceuticals' net margin of 9.70%. Corcept Therapeutics' return on equity of 20.10% beat Supernus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Corcept Therapeutics18.51% 20.10% 16.20% Supernus Pharmaceuticals 9.70%14.22%10.82% Which has preferable valuation & earnings, CORT or SUPN? Corcept Therapeutics has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorcept Therapeutics$675.04M14.03$141.21M$1.1379.51Supernus Pharmaceuticals$665.13M4.07$73.86M$1.1542.01 Does the media refer more to CORT or SUPN? In the previous week, Corcept Therapeutics had 2 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 18 mentions for Corcept Therapeutics and 16 mentions for Supernus Pharmaceuticals. Corcept Therapeutics' average media sentiment score of 0.79 beat Supernus Pharmaceuticals' score of 0.29 indicating that Corcept Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Supernus Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders believe in CORT or SUPN? 93.6% of Corcept Therapeutics shares are owned by institutional investors. 20.5% of Corcept Therapeutics shares are owned by insiders. Comparatively, 8.8% of Supernus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, CORT or SUPN? Corcept Therapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500. Do analysts rate CORT or SUPN? Corcept Therapeutics presently has a consensus target price of $135.25, suggesting a potential upside of 50.53%. Supernus Pharmaceuticals has a consensus target price of $51.50, suggesting a potential upside of 6.60%. Given Corcept Therapeutics' higher probable upside, analysts plainly believe Corcept Therapeutics is more favorable than Supernus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corcept Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57Supernus Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.80 SummaryCorcept Therapeutics beats Supernus Pharmaceuticals on 13 of the 17 factors compared between the two stocks. Get Supernus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SUPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SUPN vs. The Competition Export to ExcelMetricSupernus PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.71B$4.47B$6.10B$10.62BDividend YieldN/A0.90%5.64%4.69%P/E Ratio42.0110.9285.6627.13Price / Sales4.0720.32527.82206.05Price / Cash11.597.4926.3031.10Price / Book2.584.0512.926.67Net Income$73.86M-$134.23M$3.30B$276.23M7 Day Performance1.49%9.41%4.80%3.31%1 Month Performance5.02%8.31%8.11%10.76%1 Year Performance50.87%68.25%75.85%33.58% Supernus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SUPNSupernus Pharmaceuticals3.3565 of 5 stars$48.31-0.1%$51.50+6.6%+51.0%$2.71B$665.13M42.01580Analyst DowngradeCORTCorcept Therapeutics4.9182 of 5 stars$83.90+0.0%$135.25+61.2%+94.0%$8.84B$675.04M74.25300Insider TradeJAZZJazz Pharmaceuticals4.6787 of 5 stars$129.02+1.6%$178.93+38.7%+27.5%$7.70B$4.09B-19.172,800Insider TradePRGOPerrigo4.9304 of 5 stars$21.76+1.4%$34.00+56.3%-9.7%$2.95B$4.37B-37.518,379Positive NewsPCRXPacira BioSciences3.7215 of 5 stars$25.34+0.4%$33.40+31.8%+50.4%$1.13B$700.97M-9.12720NKTRNektar Therapeutics4.1164 of 5 stars$58.92+0.7%$91.67+55.6%+205.8%$1.11B$74.93M-6.70220OMEROmeros3.614 of 5 stars$4.18-6.3%$18.00+330.6%+21.5%$303.53MN/A-1.98210ASMBAssembly Biosciences3.6173 of 5 stars$24.63-0.2%$41.25+67.5%+56.5%$189.28M$33.25M-4.41100CPIXCumberland Pharmaceuticals0.9254 of 5 stars$3.16+2.3%N/A+150.4%$46.23M$42.07M-14.3680LLYEli Lilly and Company4.9914 of 5 stars$725.54+0.1%$939.61+29.5%-5.3%$685.75B$53.26B47.4247,000Trending NewsAnalyst ForecastJNJJohnson & Johnson4.7077 of 5 stars$181.63+1.1%$181.40-0.1%+17.6%$432.80B$90.63B19.43138,100Trending NewsAnalyst Forecast Related Companies and Tools Related Companies CORT Alternatives JAZZ Alternatives PRGO Alternatives PCRX Alternatives NKTR Alternatives OMER Alternatives ASMB Alternatives CPIX Alternatives LLY Alternatives JNJ Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SUPN) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIs This Warren’s Buffett’s #1 AI Investment?Did you know that Warren Buffett is investing in what Jeff Brown believes will be the next generation of artif...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Supernus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Supernus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
